Leuk Res: Effect of inojudan anti-treatment of relapse/refractic acute lymphoblastic leukemia patients with minimal residual disease.

Minimum residual disease (MRD) negative is a key indicator of the prognostic prognosticity of acute lymphoblastic leukemia.
In the INO-VATE trial, patients with relapsed/refractic acute lymphoblastic leukemia who received Inojudan monotherapy received greater remission and MRD-negative rates than standard chemotherapy, and improved the total survival time: HR was 0.75, and one-sided P was 0.0105.
this analysis assessed the prognostic value of MRD-negative at the end of inoju monotherapy.
study included all patients who received inoju monoantigen therapy (n s 164).
In patients with complete remission/complete remission but incomplete hematological response (CR/CRi;n s 121), the MRD-negative state (via a multi-parameter flow cytometer) is defined as a slt;1 x 10-4 embryo/nuclear cell.
treatment, 76 patients were MRD-negative.
compared to MRD-positive, CR/CRi's MRD-negative state was associated with significantly improved total lifetime and no progressive lifetime, respectively: HR (97.5% confidence interval; one-sided P value) 0.512 (97.5% CI. 13-0.835;P s 0.0009) and 0.423 (97.5% CI .256-0.699) ;P slt;0.0001).
the mrD-negative group and the MRD-positive group had a total survival of 14.1 months and 7.2 months, respectively.
treatment, the survival rate of first-time patients who reached MRD-negative increased significantly compared to MRD-positive patients, especially those with stem cell transplants.
, the results showed that MRD-negative CR/CRi patients had the best survival results in patients with relapsed/refractic acute lymphoblastic leukemia who were treated with Inojudan.
.